Improving methods to create complex alcohols and amines using nickel catalysts
Nickel Cross-Coupling Cascades with α-Heteroatom Radicals to Prepare Sterically Hindered Alcohols and Amines
This study is looking at new ways to make important building blocks for medicines by using special techniques with nickel, which could help create better drugs for patients in the future.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11009585 on NIH RePORTER |
What this research studies
This research focuses on enhancing the efficiency of forming carbon-carbon bonds that are adjacent to alcohol or amine groups, which are important in drug development. The approach involves using nickel catalysts in combination with radical generation techniques to create complex molecules more effectively. By developing new methods that overcome the limitations of traditional chemical reactions, this research aims to produce sterically hindered alcohols and amines that can be used in various applications, including pharmaceuticals. Patients may benefit indirectly from this research through the development of new drugs that arise from these improved synthetic methods.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research are individuals who may require new therapeutic options for conditions treated with alcohols and amines in drug formulations.
Not a fit: Patients who are not affected by conditions requiring new drug development or those who do not respond to alcohol or amine-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective drugs for various conditions.
How similar studies have performed: Other research has shown success with similar nickel-catalyzed approaches in organic synthesis, indicating a promising avenue for drug development.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Beleh, Omar — University of Wisconsin-Madison
- Study coordinator: Beleh, Omar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.